The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial. / Bundgaard, Johan S.; Iversen, Kasper; Pries-Heje, Mia; Ihlemann, Nikolaj; Bak, Theis S.; Østergaard, Lauge; Gill, Sabine U.; Madsen, Trine; Elming, Hanne; Jensen, Kaare T.; Bruun, Niels E.; Høfsten, Dan E.; Fuursted, Kurt; Christensen, Jens J.; Schultz, Martin; Rosenvinge, Flemming; Schønheyder, Henrik C.; Helweg-Larsen, Jannik; Køber, Lars; Torp-Pedersen, Christian; Fosbøl, Emil L.; Tønder, Niels; Moser, Claus; Bundgaard, Henning; Mogensen, Ulrik M.

In: Journal of Psychosomatic Research, Vol. 154, 110718, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Bundgaard, JS, Iversen, K, Pries-Heje, M, Ihlemann, N, Bak, TS, Østergaard, L, Gill, SU, Madsen, T, Elming, H, Jensen, KT, Bruun, NE, Høfsten, DE, Fuursted, K, Christensen, JJ, Schultz, M, Rosenvinge, F, Schønheyder, HC, Helweg-Larsen, J, Køber, L, Torp-Pedersen, C, Fosbøl, EL, Tønder, N, Moser, C, Bundgaard, H & Mogensen, UM 2022, 'The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial', Journal of Psychosomatic Research, vol. 154, 110718. https://doi.org/10.1016/j.jpsychores.2022.110718

APA

Bundgaard, J. S., Iversen, K., Pries-Heje, M., Ihlemann, N., Bak, T. S., Østergaard, L., Gill, S. U., Madsen, T., Elming, H., Jensen, K. T., Bruun, N. E., Høfsten, D. E., Fuursted, K., Christensen, J. J., Schultz, M., Rosenvinge, F., Schønheyder, H. C., Helweg-Larsen, J., Køber, L., ... Mogensen, U. M. (2022). The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial. Journal of Psychosomatic Research, 154, [110718]. https://doi.org/10.1016/j.jpsychores.2022.110718

Vancouver

Bundgaard JS, Iversen K, Pries-Heje M, Ihlemann N, Bak TS, Østergaard L et al. The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial. Journal of Psychosomatic Research. 2022;154. 110718. https://doi.org/10.1016/j.jpsychores.2022.110718

Author

Bundgaard, Johan S. ; Iversen, Kasper ; Pries-Heje, Mia ; Ihlemann, Nikolaj ; Bak, Theis S. ; Østergaard, Lauge ; Gill, Sabine U. ; Madsen, Trine ; Elming, Hanne ; Jensen, Kaare T. ; Bruun, Niels E. ; Høfsten, Dan E. ; Fuursted, Kurt ; Christensen, Jens J. ; Schultz, Martin ; Rosenvinge, Flemming ; Schønheyder, Henrik C. ; Helweg-Larsen, Jannik ; Køber, Lars ; Torp-Pedersen, Christian ; Fosbøl, Emil L. ; Tønder, Niels ; Moser, Claus ; Bundgaard, Henning ; Mogensen, Ulrik M. / The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial. In: Journal of Psychosomatic Research. 2022 ; Vol. 154.

Bibtex

@article{b8484fdd00ad4aa4804525b3a5e408a0,
title = "The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial",
abstract = "Background: The Partial-Oral versus Intravenous Antibiotic Treatment of Endocarditis Trial (POET) found that partial-oral outpatient treatment was non-inferior to conventional in-hospital intravenous treatment in patients with left-sided infective endocarditis. We examined the impact of treatment strategy on levels of anxiety and depression. Methods: Patients completed the Hospital Anxiety and Depression Scale (HADS) at randomization, at antibiotic completion, and after month 3 and month 6. Changes in anxiety and depression (each subdimension 0–21, high scores indicating worse) were calculated using a repeated measure analysis of covariance model with primary assessment after 6 months. Change in score of 1.7 represented a minimal clinical important difference (MCID). Results: Among the 400 patients enrolled in the POET trial, 263 (66%) completed HADS at randomization with reassessment rates of 86–87% at the three subsequent timepoints. Patients in the partial-oral group and the intravenous group had similar improvements after 6 months in levels of anxiety (−1.8 versus −1.6, P = 0.62) and depression (−2.1 versus −1.9, P = 0.63), although patients in the partial-oral group had numerically lower levels of anxiety and depression throughout. An improvement in MCID scores after 6 months was reported by 47% versus 45% (p = 0.80) patients for anxiety and by 51% versus 54% (p = 0.70) for depression. Conclusion: Patients with endocarditis receiving partial-oral outpatient treatment reported similar significant improvements in anxiety and depression at 6 months, as compared to conventionally treated, but numerically lower levels throughout. These findings support the usefulness of partial-oral treatment.",
keywords = "Antibiotic, Anxiety, Cardiovascular disease, Depression, Endocarditis",
author = "Bundgaard, {Johan S.} and Kasper Iversen and Mia Pries-Heje and Nikolaj Ihlemann and Bak, {Theis S.} and Lauge {\O}stergaard and Gill, {Sabine U.} and Trine Madsen and Hanne Elming and Jensen, {Kaare T.} and Bruun, {Niels E.} and H{\o}fsten, {Dan E.} and Kurt Fuursted and Christensen, {Jens J.} and Martin Schultz and Flemming Rosenvinge and Sch{\o}nheyder, {Henrik C.} and Jannik Helweg-Larsen and Lars K{\o}ber and Christian Torp-Pedersen and Fosb{\o}l, {Emil L.} and Niels T{\o}nder and Claus Moser and Henning Bundgaard and Mogensen, {Ulrik M.}",
note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
doi = "10.1016/j.jpsychores.2022.110718",
language = "English",
volume = "154",
journal = "Journal of Psychosomatic Research",
issn = "0022-3999",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial

AU - Bundgaard, Johan S.

AU - Iversen, Kasper

AU - Pries-Heje, Mia

AU - Ihlemann, Nikolaj

AU - Bak, Theis S.

AU - Østergaard, Lauge

AU - Gill, Sabine U.

AU - Madsen, Trine

AU - Elming, Hanne

AU - Jensen, Kaare T.

AU - Bruun, Niels E.

AU - Høfsten, Dan E.

AU - Fuursted, Kurt

AU - Christensen, Jens J.

AU - Schultz, Martin

AU - Rosenvinge, Flemming

AU - Schønheyder, Henrik C.

AU - Helweg-Larsen, Jannik

AU - Køber, Lars

AU - Torp-Pedersen, Christian

AU - Fosbøl, Emil L.

AU - Tønder, Niels

AU - Moser, Claus

AU - Bundgaard, Henning

AU - Mogensen, Ulrik M.

N1 - Publisher Copyright: © 2022 Elsevier Inc.

PY - 2022

Y1 - 2022

N2 - Background: The Partial-Oral versus Intravenous Antibiotic Treatment of Endocarditis Trial (POET) found that partial-oral outpatient treatment was non-inferior to conventional in-hospital intravenous treatment in patients with left-sided infective endocarditis. We examined the impact of treatment strategy on levels of anxiety and depression. Methods: Patients completed the Hospital Anxiety and Depression Scale (HADS) at randomization, at antibiotic completion, and after month 3 and month 6. Changes in anxiety and depression (each subdimension 0–21, high scores indicating worse) were calculated using a repeated measure analysis of covariance model with primary assessment after 6 months. Change in score of 1.7 represented a minimal clinical important difference (MCID). Results: Among the 400 patients enrolled in the POET trial, 263 (66%) completed HADS at randomization with reassessment rates of 86–87% at the three subsequent timepoints. Patients in the partial-oral group and the intravenous group had similar improvements after 6 months in levels of anxiety (−1.8 versus −1.6, P = 0.62) and depression (−2.1 versus −1.9, P = 0.63), although patients in the partial-oral group had numerically lower levels of anxiety and depression throughout. An improvement in MCID scores after 6 months was reported by 47% versus 45% (p = 0.80) patients for anxiety and by 51% versus 54% (p = 0.70) for depression. Conclusion: Patients with endocarditis receiving partial-oral outpatient treatment reported similar significant improvements in anxiety and depression at 6 months, as compared to conventionally treated, but numerically lower levels throughout. These findings support the usefulness of partial-oral treatment.

AB - Background: The Partial-Oral versus Intravenous Antibiotic Treatment of Endocarditis Trial (POET) found that partial-oral outpatient treatment was non-inferior to conventional in-hospital intravenous treatment in patients with left-sided infective endocarditis. We examined the impact of treatment strategy on levels of anxiety and depression. Methods: Patients completed the Hospital Anxiety and Depression Scale (HADS) at randomization, at antibiotic completion, and after month 3 and month 6. Changes in anxiety and depression (each subdimension 0–21, high scores indicating worse) were calculated using a repeated measure analysis of covariance model with primary assessment after 6 months. Change in score of 1.7 represented a minimal clinical important difference (MCID). Results: Among the 400 patients enrolled in the POET trial, 263 (66%) completed HADS at randomization with reassessment rates of 86–87% at the three subsequent timepoints. Patients in the partial-oral group and the intravenous group had similar improvements after 6 months in levels of anxiety (−1.8 versus −1.6, P = 0.62) and depression (−2.1 versus −1.9, P = 0.63), although patients in the partial-oral group had numerically lower levels of anxiety and depression throughout. An improvement in MCID scores after 6 months was reported by 47% versus 45% (p = 0.80) patients for anxiety and by 51% versus 54% (p = 0.70) for depression. Conclusion: Patients with endocarditis receiving partial-oral outpatient treatment reported similar significant improvements in anxiety and depression at 6 months, as compared to conventionally treated, but numerically lower levels throughout. These findings support the usefulness of partial-oral treatment.

KW - Antibiotic

KW - Anxiety

KW - Cardiovascular disease

KW - Depression

KW - Endocarditis

U2 - 10.1016/j.jpsychores.2022.110718

DO - 10.1016/j.jpsychores.2022.110718

M3 - Journal article

C2 - 35078079

AN - SCOPUS:85123194068

VL - 154

JO - Journal of Psychosomatic Research

JF - Journal of Psychosomatic Research

SN - 0022-3999

M1 - 110718

ER -

ID: 291221405